title: [New therapies in pediatric rheumatology].
abstract: Biotherapies are recent treatments, which target molecules implicated in the pathogenesis of inflammatory diseases. In pediatric rheumatology, we use anti-TNF-alpha and abatacept in JIA patients with polyarticular involvement, whereas anti-IL-6 and anti-IL-1 blockers are efficacious in the systemic form of JIA and other auto-inflammatory conditions. These new treatments have significantly improved the control of articular and systemic inflammation and the prognosis of rheumatic diseases. Their effect and their safety on the long-term need to be assessed on large cohorts of patients. Due to the impact of these chronic illnesses on the young patient and its family, and the required specific knowledge, the care of these children should be provided by a multidisciplinary team linked to a centre of competence.
authors.affiliation: Unité romande de rhumatologie pédiatrique, CHUV, Lausanne.
authors.forename: Felicitas
authors.initials: F
authors.lastname: Bellutti Enders
authors.forename: Annette
authors.initials: A
authors.lastname: Von Scheven-Gête
authors.forename: Federica
authors.initials: F
authors.lastname: Vanoni
authors.forename: Béatrice
authors.initials: B
authors.lastname: Fonjallaz
authors.forename: Michaël
authors.initials: M
authors.lastname: Hofer
mesh_terms: D001688:Biological Products / Q000627:therapeutic use; D002648:Child; D006801:Humans; D012216:Rheumatic Diseases / Q000188:drug therapy*
chemical_list: D001688:Biological Products